Page last updated: 2024-09-03

gefitinib and transforming growth factor alpha

gefitinib has been researched along with transforming growth factor alpha in 36 studies

Compound Research Comparison

Studies
(gefitinib)
Trials
(gefitinib)
Recent Studies (post-2010)
(gefitinib)
Studies
(transforming growth factor alpha)
Trials
(transforming growth factor alpha)
Recent Studies (post-2010) (transforming growth factor alpha)
5,2315662,9194,30144623

Research

Studies (36)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's25 (69.44)29.6817
2010's11 (30.56)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Ciardiello, F1
Bianco, AR; Bianco, R; Caputo, R; Ciardiello, F; Cuccato, S; Damiano, V; De Placido, S; Fontanini, G; Tortora, G1
Arteaga, CL; Bianco, R; Moulder, SL; Muthuswamy, SK; Simpson, JF; Yakes, FM1
Bianco, AR; Biroccio, A; Borriello, G; Caputo, R; Ciardiello, F; Del Bufalo, D; Tortora, G; Zupi, G1
Fujimura, M; Hidaka, T; Saito, S1
Barrow, D; Gee, JM; Harper, ME; Hutcheson, IR; Jones, HE; Knowlden, JM; Madden, T; Nicholson, RI; Wakeling, AE1
Attoub, S; Bruyneel, E; Emami, S; Gespach, C; Mareel, M; May, FE; Nguyen, QD; Rodrigue, CM; Rodrigues, S; Thim, L; Westley, BR1
Ono, M1
Barnard, GF; Inoue, H; Ishii, H; Ishikawa, K; Mimori, K; Mori, M; Ohta, M; Utsunomiya, T; Yamashita, K; Yoshinaga, K1
Bekele, BN; Doan, D; El-Naggar, AK; Holsinger, FC; Jasser, SA; Kim, S; Mandal, M; McMurphy, AB; Myers, JN; Schiff, BA; Sherman, SI; Yeung, SC; Yigitbasi, OG; Younes, MN; Zhou, G1
Barbu, V; Cacheux, W; Clergue, F; Desbois-Mouthon, C; Housset, C; Poupon, R; Rey, C; Rosmorduc, O; Schiffer, E; Wendum, D1
Kishida, O; Kiyohara, T; Miyazaki, T; Miyazaki, Y; Murayama, Y; Ogasa, M; Shimomura, I; Shinomura, Y; Tsutsui, S; Watabe, K; Yamamoto, T2
Bell, DW; Haber, DA; Louis, DN; Riemenschneider, MJ1
Gooding, WE; Grandis, JR; Lui, VW; Siegfried, JM; Thomas, SM; Wentzel, AL1
Daigo, Y; Hayama, S; Inai, K; Ishikawa, N; Kato, T; Kohno, N; Murakami, H; Nakamura, Y; Nishimura, H; Takano, A; Takeshima, Y; Taniwaki, M; Tsuchiya, E1
Brockstein, BE; Cohen, EE; Dekker, A; Huo, D; Kane, MA; List, MA; Mauer, AM; Mehrotra, B; Pierce, C; Vokes, EE1
Akizawa, T; Hatamura, I; Negi, S; Orita, H; Saji, F; Sakaguchi, T; Shibata, M; Shiizaki, K1
Matsumoto, K; Murawaki, Y; Nagahara, T; Okano, J1
Abbruzzese, JL; Baker, CH; Cognetti, F; McConkey, DJ; Pino, MS; Shrader, M; Xiong, HQ1
Arteaga, CL; Carpenter, G; Gazdar, AF; Muthuswamy, SK; Narasanna, A; Perez-Torres, M; Wang, SE; Wu, FY; Xiang, B; Yang, S1
Desbois-Mouthon, C; Fartoux, L; Poupon, R; Rosmorduc, O1
Baker, CH; Bekele, N; Fidler, IJ; Herbst, RS; Langley, RR; O'Reilly, MS; Onn, A; Tang, XM; Tsan, RZ; Wu, W1
Davidson, C; Hardie, WD; Ikegami, M; Korfhagen, TR; Le Cras, TD; Leikauf, GD; Prestridge, A; Whitsett, JA1
Fennell, DA; Johnston, PG; Kelly, DM; Kyula, J; Longley, DB; Stokesberry, S; Van Schaeybroeck, S1
Bollinger, N; Joslin, EJ; Lauffenburger, DA; Opresko, LK; Shankaran, H; Wiley, HS1
Fenning, CS; Fenton, A; Johnston, PG; Kyula, JN; Longley, DB; Sasazuki, T; Shirasawa, S; Van Schaeybroeck, S1
An, SJ; Chen, ZH; Cheng, H; Dong, S; Wu, YL; Zhang, XC; Zhang, YF1
Gooding, WE; Grandis, JR; Gubish, CT; Siegfried, JM; Stabile, LP; Xu, H1
Hashimoto, M; Koizumi, F; Minakata, K; Moriyama, H; Murakami, A; Nara, T; Nishio, K; Nurwidya, F; Seyama, K; Tajima, K; Takahashi, F; Takahashi, K; Yae, S1
Dong, X; He, C; Jiang, H; Jiang, X; Ma, L; Pan, S; Qiao, H; Sun, X; Tan, G; Wei, Z; Zhai, B; Zhao, D1
Chan, DC; Jensen, RT; Mantey, SA; Moody, TW; Moreno, P1
Böhning, E; Calvisi, DF; Cigliano, A; Dombrowski, F; Evert, M; Günther, J; Merz, J; Peters, K; Pilo, MG; Ribback, S; Sailer, V; Steinmüller, F; Utpatel, K1
Szabo, E; von Achenbach, C; Weller, M1
Chen, C; Liang, Z; Liu, D; Poteet, E; Van Buren, G; Yao, Q1
Ando, K; Arata, S; Homma, M; Homma, T; Kishino, Y; Kusumoto, S; Manabe, R; Ohba, M; Ohmori, T; Sagara, H; Takimoto, M; Tsurutani, J; Yamaoka, T1

Reviews

2 review(s) available for gefitinib and transforming growth factor alpha

ArticleYear
Epidermal growth factor receptor tyrosine kinase inhibitors as anticancer agents.
    Drugs, 2000, Volume: 60 Suppl 1

    Topics: Administration, Oral; Antibodies, Monoclonal; Antineoplastic Agents; Disease Progression; ErbB Receptors; Gefitinib; Humans; Ligands; Neoplasms; Protein-Tyrosine Kinases; Quinazolines; Signal Transduction; Transforming Growth Factor alpha

2000
[Anti-EGFR therapy: towards a "à la carte" targeting of hepatocellular carcinoma].
    Gastroenterologie clinique et biologique, 2006, Volume: 30, Issue:10

    Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cetuximab; Clinical Trials, Phase II as Topic; Disease Models, Animal; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Ligands; Liver Neoplasms; Multicenter Studies as Topic; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Quinazolines; Rats; Signal Transduction; Transforming Growth Factor alpha

2006

Trials

1 trial(s) available for gefitinib and transforming growth factor alpha

ArticleYear
Phase II trial of gefitinib 250 mg daily in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, Dec-01, Volume: 11, Issue:23

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Squamous Cell; Disease-Free Survival; Drug Administration Schedule; Female; Gefitinib; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Quality of Life; Quinazolines; Salvage Therapy; Survival Rate; Transforming Growth Factor alpha; Vascular Endothelial Growth Factor A

2005

Other Studies

33 other study(ies) available for gefitinib and transforming growth factor alpha

ArticleYear
Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2001, Volume: 7, Issue:5

    Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Disease Models, Animal; Drug Synergism; Endothelial Growth Factors; ErbB Receptors; Female; Fibroblast Growth Factor 2; Gefitinib; Growth Substances; Humans; Immunohistochemistry; Inhibitory Concentration 50; Lymphokines; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasms, Experimental; Neovascularization, Pathologic; Protein-Tyrosine Kinases; Quinazolines; Transforming Growth Factor alpha; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors; Xenograft Model Antitumor Assays

2001
Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo.
    Cancer research, 2001, Dec-15, Volume: 61, Issue:24

    Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Catalytic Domain; Cell Cycle; Cell Division; Cell Survival; Drug Synergism; Enzyme Inhibitors; ErbB Receptors; Female; Gefitinib; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Phosphorylation; Proto-Oncogene Mas; Quinazolines; Receptor, ErbB-2; Signal Transduction; Substrate Specificity; Transforming Growth Factor alpha; Trastuzumab; Tumor Cells, Cultured; Xenograft Model Antitumor Assays

2001
ZD1839 (IRESSA), an EGFR-selective tyrosine kinase inhibitor, enhances taxane activity in bcl-2 overexpressing, multidrug-resistant MCF-7 ADR human breast cancer cells.
    International journal of cancer, 2002, Mar-20, Volume: 98, Issue:3

    Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Breast Neoplasms; Bridged-Ring Compounds; Cell Division; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Inhibitors; ErbB Receptors; Female; Fibroblast Growth Factor 2; Gefitinib; Humans; Phosphorylation; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-bcl-2; Quinazolines; Taxoids; Transfection; Transforming Growth Factor alpha; Tumor Cells, Cultured

2002
Selective inhibition of the epidermal growth factor receptor by ZD1839 decreases the growth and invasion of ovarian clear cell adenocarcinoma cells.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2002, Volume: 8, Issue:7

    Topics: Adenocarcinoma, Clear Cell; Animals; Antineoplastic Agents; Cell Division; Cytokines; Endothelial Growth Factors; ErbB Receptors; Female; Gefitinib; Growth Substances; Humans; Immunoenzyme Techniques; In Vitro Techniques; Intercellular Signaling Peptides and Proteins; Lymphokines; Mice; Mice, SCID; Ovarian Neoplasms; Phosphorylation; Protein-Tyrosine Kinases; Quinazolines; Transforming Growth Factor alpha; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors

2002
Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells.
    Endocrinology, 2003, Volume: 144, Issue:3

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Cell Division; Dimerization; Drug Resistance, Neoplasm; ErbB Receptors; Flavonoids; Gefitinib; Humans; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinases; Phosphorylation; Quinazolines; Receptor, ErbB-2; RNA, Messenger; Tamoxifen; Transforming Growth Factor alpha; Trastuzumab; Tumor Cells, Cultured

2003
Selective abrogation of the proinvasive activity of the trefoil peptides pS2 and spasmolytic polypeptide by disruption of the EGF receptor signaling pathways in kidney and colonic cancer cells.
    Oncogene, 2003, Jul-17, Volume: 22, Issue:29

    Topics: Amphiregulin; Animals; Cells, Cultured; Colonic Neoplasms; Dogs; EGF Family of Proteins; Enzyme Inhibitors; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Genes, src; Glycoproteins; Growth Substances; Humans; Intercellular Signaling Peptides and Proteins; Kidney; Mucins; Muscle Proteins; Mutation; Neoplasm Invasiveness; Neuropeptides; Peptides; Phosphatidylinositol 3-Kinases; Proteins; Quinazolines; Receptors, Thromboxane; Signal Transduction; Transforming Growth Factor alpha; Trefoil Factor-1; Trefoil Factor-2; Trefoil Factor-3; Tumor Suppressor Proteins

2003
[Screening of antiangiogenic compound].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2004, Volume: 31, Issue:4

    Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Cell Line, Tumor; Cyclooxygenase 2; Drug Screening Assays, Antitumor; Gefitinib; Humans; Interleukin-1; Isoenzymes; Lung Neoplasms; Membrane Proteins; Mice; Prostaglandin-Endoperoxide Synthases; Quinazolines; Transforming Growth Factor alpha

2004
Coexpression of matrix metalloproteinase-7 (MMP-7) and epidermal growth factor (EGF) receptor in colorectal cancer: an EGF receptor tyrosine kinase inhibitor is effective against MMP-7-expressing cancer cells.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2004, Dec-15, Volume: 10, Issue:24

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Apoptosis; Cell Nucleus; Colorectal Neoplasms; Cytoplasm; DNA-Binding Proteins; Epidermal Growth Factor; ErbB Receptors; Female; Gefitinib; Humans; Immunoenzyme Techniques; Male; Matrix Metalloproteinase 7; Middle Aged; Phosphorylation; Protein Transport; Quinazolines; Smad4 Protein; Trans-Activators; Transfection; Transforming Growth Factor alpha; Tumor Cells, Cultured

2004
Epidermal growth factor receptor (EGFR) is overexpressed in anaplastic thyroid cancer, and the EGFR inhibitor gefitinib inhibits the growth of anaplastic thyroid cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2004, Dec-15, Volume: 10, Issue:24

    Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma; Carcinoma, Papillary; Cell Proliferation; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Humans; Mice; Mice, Nude; Paclitaxel; Phosphorylation; Quinazolines; Thyroid Neoplasms; Transforming Growth Factor alpha; Tumor Cells, Cultured

2004
Gefitinib, an EGFR inhibitor, prevents hepatocellular carcinoma development in the rat liver with cirrhosis.
    Hepatology (Baltimore, Md.), 2005, Volume: 41, Issue:2

    Topics: Alkylating Agents; Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Diethylnitrosamine; ErbB Receptors; Gefitinib; Liver Cirrhosis; Liver Neoplasms; Male; Quinazolines; Rats; Rats, Wistar; Signal Transduction; Transforming Growth Factor alpha

2005
Gefitinib (Iressa, ZD1839) inhibits SN38-triggered EGF signals and IL-8 production in gastric cancer cells.
    Cancer chemotherapy and pharmacology, 2005, Volume: 55, Issue:6

    Topics: Amphiregulin; Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Drug Screening Assays, Antitumor; EGF Family of Proteins; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Glycoproteins; Heparin-binding EGF-like Growth Factor; Humans; Intercellular Signaling Peptides and Proteins; Interleukin-8; Irinotecan; Phosphorylation; Quinazolines; Reactive Oxygen Species; Signal Transduction; Stomach Neoplasms; Transforming Growth Factor alpha; Tyrosine

2005
Gefitinib ("Iressa", ZD1839) inhibits SN38-triggered EGF signals and IL-8 production in gastric cancer cells.
    Cancer chemotherapy and pharmacology, 2005, Volume: 55, Issue:4

    Topics: Adenocarcinoma; Amphiregulin; Antineoplastic Agents; Camptothecin; EGF Family of Proteins; ErbB Receptors; Gefitinib; Glycoproteins; Humans; Intercellular Signaling Peptides and Proteins; Interleukin-8; Irinotecan; Metalloproteases; Phosphorylation; Quinazolines; Reactive Oxygen Species; Stomach Neoplasms; Transforming Growth Factor alpha; Tumor Cells, Cultured

2005
Pulmonary adenocarcinomas with mutant epidermal growth factor receptors.
    The New England journal of medicine, 2005, Apr-21, Volume: 352, Issue:16

    Topics: Adenocarcinoma; Antineoplastic Agents; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Humans; Ligands; Lung Neoplasms; Mutation, Missense; Quinazolines; Sequence Deletion; Stromal Cells; Transforming Growth Factor alpha

2005
Gastrin-releasing peptide receptor mediates activation of the epidermal growth factor receptor in lung cancer cells.
    Neoplasia (New York, N.Y.), 2005, Volume: 7, Issue:4

    Topics: Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Death; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Enzyme Activation; ErbB Receptors; Gefitinib; Humans; Immunoblotting; Immunoprecipitation; Ligands; Lung Neoplasms; MAP Kinase Signaling System; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Phosphorylation; Quinazolines; Receptors, Bombesin; Signal Transduction; Transforming Growth Factor alpha

2005
Increases of amphiregulin and transforming growth factor-alpha in serum as predictors of poor response to gefitinib among patients with advanced non-small cell lung cancers.
    Cancer research, 2005, Oct-15, Volume: 65, Issue:20

    Topics: Adult; Aged; Aged, 80 and over; Amphiregulin; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; EGF Family of Proteins; Enzyme-Linked Immunosorbent Assay; Female; Gefitinib; Glycoproteins; Humans; Intercellular Signaling Peptides and Proteins; Lung Neoplasms; Male; Middle Aged; Quinazolines; Transforming Growth Factor alpha

2005
[Enhanced expression of EGFR, TGF-alpha, EGF in hyperplastic parathyroid glands in established stage of renal failure in rats].
    Clinical calcium, 2005, Volume: 15 Suppl 1

    Topics: Animals; Cell Proliferation; Disease Models, Animal; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Hyperplasia; Intracellular Signaling Peptides and Proteins; Male; Parathyroid Glands; Parathyroid Hormone; Phosphorus, Dietary; Quinazolines; Rats; Rats, Sprague-Dawley; Renal Insufficiency; Time Factors; Transforming Growth Factor alpha

2005
Gefitinib and the modulation of the signaling pathways downstream of epidermal growth factor receptor in human liver cancer cells.
    Journal of gastroenterology, 2006, Volume: 41, Issue:2

    Topics: ErbB Receptors; Gefitinib; Humans; Liver Neoplasms; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Transforming Growth Factor alpha; Tumor Cells, Cultured

2006
Transforming growth factor alpha expression drives constitutive epidermal growth factor receptor pathway activation and sensitivity to gefitinib (Iressa) in human pancreatic cancer cell lines.
    Cancer research, 2006, Apr-01, Volume: 66, Issue:7

    Topics: Animals; Antineoplastic Agents; Cell Growth Processes; Cell Line, Tumor; Drug Screening Assays, Antitumor; ErbB Receptors; Gefitinib; Humans; Male; Mice; Mice, Nude; Pancreatic Neoplasms; Phosphorylation; Quinazolines; Signal Transduction; Transforming Growth Factor alpha; Xenograft Model Antitumor Assays

2006
HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors.
    Cancer cell, 2006, Volume: 10, Issue:1

    Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Apoptosis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Resistance, Neoplasm; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Mice; Mice, Nude; Models, Biological; Morpholines; Mutation; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; RNA, Small Interfering; Transforming Growth Factor alpha; Trastuzumab; Xenograft Model Antitumor Assays

2006
Expression of epidermal growth factor (EGF)/transforming growth factor-alpha by human lung cancer cells determines their response to EGF receptor tyrosine kinase inhibition in the lungs of mice.
    Molecular cancer therapeutics, 2007, Volume: 6, Issue:10

    Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Blotting, Western; Cell Proliferation; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Gene Dosage; Humans; Lung Neoplasms; Male; Mice; Mice, Nude; Phosphorylation; Purines; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; Transforming Growth Factor alpha; Xenograft Model Antitumor Assays

2007
EGF receptor tyrosine kinase inhibitors diminish transforming growth factor-alpha-induced pulmonary fibrosis.
    American journal of physiology. Lung cellular and molecular physiology, 2008, Volume: 294, Issue:6

    Topics: Animals; Bronchoalveolar Lavage Fluid; Doxycycline; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression; Humans; Mice; Pulmonary Fibrosis; Quinazolines; RNA, Messenger; Transforming Growth Factor alpha

2008
Src and ADAM-17-mediated shedding of transforming growth factor-alpha is a mechanism of acute resistance to TRAIL.
    Cancer research, 2008, Oct-15, Volume: 68, Issue:20

    Topics: ADAM Proteins; ADAM17 Protein; Apoptosis; Colorectal Neoplasms; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; HCT116 Cells; HT29 Cells; Humans; Metalloproteases; Quinazolines; Receptor, ErbB-2; Receptors, TNF-Related Apoptosis-Inducing Ligand; Receptors, Tumor Necrosis Factor; Recombinant Proteins; src-Family Kinases; TNF-Related Apoptosis-Inducing Ligand; Transforming Growth Factor alpha

2008
Structure of the EGF receptor transactivation circuit integrates multiple signals with cell context.
    Molecular bioSystems, 2010, Volume: 6, Issue:7

    Topics: Cell Line; Dose-Response Relationship, Drug; Epithelial Cells; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Flavonoids; Gefitinib; Gene Regulatory Networks; Hepatocyte Growth Factor; Humans; Imidazoles; Ligands; Lysophospholipids; Mammary Glands, Human; Phosphorylation; Pyridines; Quinazolines; Signal Transduction; Transcriptional Activation; Transforming Growth Factor alpha

2010
Oncogenic Kras promotes chemotherapy-induced growth factor shedding via ADAM17.
    Cancer research, 2011, Feb-01, Volume: 71, Issue:3

    Topics: ADAM Proteins; ADAM17 Protein; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cell Line, Tumor; Cetuximab; Colorectal Neoplasms; Gefitinib; Genes, ras; HCT116 Cells; HT29 Cells; Humans; MAP Kinase Kinase 1; MAP Kinase Kinase 2; Mice; Mice, Inbred BALB C; Mice, SCID; Point Mutation; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Transforming Growth Factor alpha

2011
Molecular mechanism of the schedule-dependent synergistic interaction in EGFR-mutant non-small cell lung cancer cell lines treated with paclitaxel and gefitinib.
    Journal of hematology & oncology, 2011, Jan-21, Volume: 4

    Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Paclitaxel; Quinazolines; Signal Transduction; Transforming Growth Factor alpha

2011
Dual blockade of EGFR and c-Met abrogates redundant signaling and proliferation in head and neck carcinoma cells.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2011, Jul-01, Volume: 17, Issue:13

    Topics: Animals; Antineoplastic Agents; Carcinoma; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Female; Gefitinib; Head and Neck Neoplasms; Hepatocyte Growth Factor; Humans; Mice; Mice, SCID; Mitogen-Activated Protein Kinases; Neoplasm Invasiveness; Neoplasms, Squamous Cell; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-met; Quinazolines; Signal Transduction; Squamous Cell Carcinoma of Head and Neck; Transforming Growth Factor alpha; Wound Healing; Xenograft Model Antitumor Assays

2011
Hypoxia induces gefitinib resistance in non-small-cell lung cancer with both mutant and wild-type epidermal growth factor receptors.
    Cancer science, 2012, Volume: 103, Issue:11

    Topics: Carcinoma, Non-Small-Cell Lung; Cell Hypoxia; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Lung Neoplasms; MAP Kinase Signaling System; Mutation; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Transforming Growth Factor alpha; Up-Regulation

2012
Upregulation of HIF-2α induced by sorafenib contributes to the resistance by activating the TGF-α/EGFR pathway in hepatocellular carcinoma cells.
    Cellular signalling, 2014, Volume: 26, Issue:5

    Topics: Animals; Antineoplastic Agents; Basic Helix-Loop-Helix Transcription Factors; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Niacinamide; Phenylurea Compounds; Quinazolines; Signal Transduction; Sorafenib; Transforming Growth Factor alpha; Up-Regulation

2014
SR48692 inhibits non-small cell lung cancer proliferation in an EGF receptor-dependent manner.
    Life sciences, 2014, Mar-28, Volume: 100, Issue:1

    Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Gefitinib; Gene Knockdown Techniques; Humans; Lung Neoplasms; Phosphorylation; Protein Processing, Post-Translational; Pyrazoles; Quinazolines; Quinolines; Receptors, Neurotensin; RNA, Small Interfering; Transcriptional Activation; Transforming Growth Factor alpha

2014
The Epidermal Growth Factor Receptor (EGFR) Inhibitor Gefitinib Reduces but Does Not Prevent Tumorigenesis in Chemical and Hormonal Induced Hepatocarcinogenesis Rat Models.
    International journal of molecular sciences, 2016, Sep-23, Volume: 17, Issue:10

    Topics: Animals; Cell Proliferation; Disease Models, Animal; Drug Administration Schedule; ErbB Receptors; Female; Gefitinib; Immunohistochemistry; Islets of Langerhans Transplantation; Liver Neoplasms, Experimental; Male; Nitrosamines; Protein Kinase Inhibitors; Quinazolines; ras Proteins; Rats; Rats, Inbred Lew; Sodium-Glucose Transporter 1; Thyroid Epithelial Cells; TOR Serine-Threonine Kinases; Transforming Growth Factor alpha

2016
Epidermal growth factor receptor and ligand family expression and activity in glioblastoma.
    Journal of neurochemistry, 2018, Volume: 147, Issue:1

    Topics: Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Cell Nucleus; Cell Proliferation; Cetuximab; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Glioblastoma; Humans; Ligands; Transforming Growth Factor alpha

2018
Mesothelin and TGF-α predict pancreatic cancer cell sensitivity to EGFR inhibitors and effective combination treatment with trametinib.
    PloS one, 2019, Volume: 14, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cell Cycle; Cell Proliferation; Cetuximab; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; GPI-Linked Proteins; Humans; Mesothelin; Pancreatic Neoplasms; Pyridones; Pyrimidinones; Signal Transduction; Transforming Growth Factor alpha; Tumor Cells, Cultured

2019
Blockade of EGFR Activation Promotes TNF-Induced Lung Epithelial Cell Apoptosis and Pulmonary Injury.
    International journal of molecular sciences, 2019, Aug-17, Volume: 20, Issue:16

    Topics: ADAM17 Protein; Animals; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line; Epithelial Cells; ErbB Receptors; Gefitinib; Heparin-binding EGF-like Growth Factor; Humans; Lung; Lung Injury; Lung Neoplasms; Mice; Mice, Transgenic; Models, Animal; p38 Mitogen-Activated Protein Kinases; Pneumonia; Protein Kinase Inhibitors; Transforming Growth Factor alpha; Tumor Necrosis Factor-alpha

2019
chemdatabank.com